01 diciembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study

Dan Rusinaru MD, PhD1, Mathias Vrolix MD2, Stefan Verheye MD3, Saqib Chowdhary MD, PhD4, Danny Schoors MD5, Carlo Di Mario MD, PhD6, Walter Desmet MD, PhD7, Dennis J. Donohoe MD8, John A. Ormiston MBCHB, PhD9, Charlene Knape MT8, Hiram Bezerra MD, PhD10, Alexandra Lansky MD11, William Wijns MD, PhD1,* andon behalf of the DESSOLVE II Investigators

Objectives: We studied coronary vasomotion in patients treated with the Mistent® absorbable polymer sirolimus-eluting stent (APSES) and in patients implanted with the Endeavor® zotarolimus-eluting stent (ZES).

01 diciembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Femoral access-related complications during percutaneous transcatheter aortic valve implantation comparing single versus double Prostar XL device closure

Nawsad Saleh MD, PhD*, Rodney De Palma MRCP (UK), Magnus Settergren MD, PhD andAndreas Rück MD, PhD

Objectives: To evaluate the efficacy and safety of a double Prostar XL suture-based closure technique compared to a conventional single Prostar XL technique in elective transcatheter aortic valve implantation (TAVI) via the common femoral artery.

01 diciembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Transcatheter closure of postmyocardial infarction, iatrogenic, and postoperative ventricular septal defects: The Mayo Clinic experience

Alexander C. Egbe MD, MPH1, Joseph T. Poterucha DO2, Charanjit S. Rihal MD, MBA1, Nathaniel W. Taggart MD2, Frank Cetta MD2, Allison K. Cabalka MD2, Peter M. Pollak MD2, Guy S. Reeder MD1 andDonald J. Hagler MD2,*

Objectives: To determine event-free survival after transcatheter closure of ventricular septal defect (VSD), and to identify predictors of adverse events (AE) in post myocardial infarction VSD (post-MI VSD) subgroup.

01 diciembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Poor mobility predicts adverse outcome better than other frailty indices in patients undergoing transcatheter aortic valve implantation

James Cockburn MD, Meera Sundar Singh, Nur Hanis Mohammed Rafi, Maureen Dooley MBBS, Nevil Hutchinson MD, Andrew Hill MD, Uday Trivedi MD, Adam de Belder MD andDavid Hildick-Smith MD*

Background: Surgical risk scoring systems are poor at predicting outcome in patients undergoing transcatheter aortic valve implantation (TAVI). Frailty indices might more accurately predict outcome. Aims: To examine multiple frailty indices as markers of performance to see whether they predict outcomes both in the shorter (30 days) and longer terms (5 years) in patients who have undergone TAVI.

01 diciembre 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. First in human implantation of the mechanical expanding Lotus® valve in degenerated surgical valves in mitral position

Ulrich Schaefer MD1,*, Lenard Conradi MD2, Edith Lubos MD1, Florian Deuschl MD1, Niklas Schofer MD1, Moritz Seiffert MD1, Hendrik Treede MD2, Johannes Schirmer MD2, Hermann Reichenspurner MD2 andStefan Blankenberg MD1

Introduction: Implantation of transcatheter heart valves (THV) into degenerated surgical valves is an emerging therapy for selected high-risk patients. Although, CE mark of most THV is limited for native aortic valvular stenosis, transcatheter valve implantation into degenerated bioprostheses, even in mitral position is very intriguing.

01 octubre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy CME

Dean J. Kereiakes, MD∗; Robert W. Yeh, MD, MSc†,‡; Joseph M. Massaro, PhD†,§; Priscilla Driscoll-Shempp, MBA†; Donald E. Cutlip, MD†,‖; P. Gabriel Steg, MD¶,#,∗∗; Anthony H. Gershlick, MBBS††; Harald Darius, MD, PhD‡‡; Ian T. Meredith, MD, PhD§§; John Ormiston, Mb, Chb‖‖; Jean-François Tanguay, MD¶¶; Stephan Windecker, MD##; Kirk N. Garratt, MD, MSc∗∗∗; David E. Kandzari, MD†††; David P. Lee, MD‡‡‡; Daniel I. Simon, MD§§§; Adrian Corneliu Iancu, MD‖‖‖; Jaroslaw Trebacz, MD, PhD¶¶¶; Laura Mauri, MD, MSc†,###

Objectives: This study sought to compare rates of stent thrombosis and major adverse cardiac and cerebrovascular events (MACCE) (composite of death, myocardial infarction, or stroke) after coronary stenting with drug-eluting stents (DES) versus bare-metal stents (BMS) in patients who participated in the DAPT (Dual Antiplatelet Therapy) study, an international multicenter randomized trial comparing 30 versus 12 months of dual antiplatelet therapy in subjects undergoing coronary stenting with either DES or BMS.

01 octubre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention. The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis)

Renato Valenti, MD; Rossella Marcucci, MD; Vincenzo Comito, MD; Marco Marrani, MD; Giulia Cantini, MD; Angela Migliorini, MD; Guido Parodi, MD; Gian Franco Gensini, MD; Rosanna Abbate, MD; David Antoniucci, MD

Objectives: This study sought to investigate the efficacy of prasugrel compared with clopidogrel in clopidogrel nonresponders.

01 octubre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes. Insights From the National Cardiovascular Data Registry

David M. Safley, MD∗,†; Lakshmi Venkitachalam, PhD‡; Kevin F. Kennedy, MS∗; David J. Cohen, MD, MSc

Objectives: This study investigates the effects of glycoprotein IIb/IIIa inhibitors (GPIs) on outcomes after percutaneous coronary intervention (PCI).

01 octubre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Drug-Coated Balloons Versus Second-Generation Drug-Eluting Stents for the Management of Recurrent Multimetal-Layered In-Stent Restenosis

Hiroyoshi Kawamoto, MD∗,†; Neil Ruparelia, MBBS, DPhil∗,†,‡; Azeem Latib, MD∗,†; Tadashi Miyazaki, MD∗,†; Katsumasa Sato, MD∗,†; Antonio Mangieri, MD∗; Rachele Contri, MD∗; Stefano Stella, MD∗; Filippo Figini, MD∗,†; Alaide Chieffo, MD∗; Mauro Carlino, MD∗; Matteo Montorfano, MD∗; Antonio Colombo, MD∗,†

Objectives: This study aimed to investigate the clinical outcomes of patients presenting with recurrent drug-eluting stent (DES) in-stent restenosis (ISR) treated with a second-generation DES or with a drug-coated balloon (DCB).

01 octubre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement. The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation)

Marco Barbanti, MD∗; Simona Gulino, MD∗; Piera Capranzano, MD∗; Sebastiano Immè, MD∗; Carmelo Sgroi, MD∗; Claudia Tamburino, MD∗; Yohei Ohno, MD∗,†; Guilherme F. Attizzani, MD∗,‡; Martina Patanè, MD∗; Rita Sicuso, MD∗; Gerlando Pilato, MD∗; Alessio Di Landro, MD∗; Denise Todaro, MD∗; Emanuela Di Simone, MD∗; Andrea Picci, MD∗; Giuliana Giannetto, MD∗; Giuliano Costa, MD∗; Wanda Deste, MD∗; Daniela Giannazzo, MD∗; Carmelo Grasso, MD∗; Davide Capodanno, MD, PhD∗; Corrado Tamburino, MD, PhD∗,§

Objectives: The purpose of this study was to investigate the effect of the RenalGuard System (PLC Medical Systems, Milford, Massachusetts) on prevention of acute kidney injury (AKI) in patients undergoing transcatheter aortic valve replacement (TAVR).

01 octubre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Increased Risk of Cerebral Embolization After Implantation of a Balloon-Expandable Aortic Valve Without Prior Balloon Valvuloplasty

Klaudija Bijuklic, MD∗; Timo Haselbach, MD†; Julian Witt, MD‡; Korff Krause, MD‡; Lorenz Hansen, MD†; Ralf Gehrckens, MD§; Friedrich-Christian Rieß, MD, PhD†; Joachim Schofer, MD, PhD∗,‖

Objectives: The purpose of this study was to analyze the effect of transcatheter aortic valve replacement (TAVR) without versus with prior balloon aortic valvuloplasty (BAV) on the risk of cerebral embolization in patients who receive a balloon-expandable valve.

01 noviembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease. A Patient-Level Pooled Analysis of 6,081 Patients

Raffaele Piccolo, MD∗; Thomas Pilgrim, MD∗; Dik Heg, PhD†; Anna Franzone, MD∗; Julie Rat-Wirtzler, MSc†; Lorenz Räber, MD∗; Sigmund Silber, MD‡; Patrick W. Serruys, MD§; Peter Jüni, MD‖; Stephan Windecker, MD∗

Objectives: The purpose of this study was to compare the 2-year safety and effectiveness of new- versus early-generation drug-eluting stents (DES) according to the severity of coronary artery disease (CAD) as assessed by the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score.

01 noviembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Diagnostic and Prognostic Implications of Coronary Flow Capacity. A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart Disease

Tim P. van de Hoef, MD, PhD∗,†; Mauro Echavarría-Pinto, MD†,‡; Martijn A. van Lavieren, MSc∗; Martijn Meuwissen, MD, PhD§; Patrick W.J.C. Serruys, MD, PhD‡,‖; Jan G.P. Tijssen, PhD∗; Stuart J. Pocock, PhD†,¶; Javier Escaned, MD, PhD†,#; Jan J. Piek, MD, PhD∗

Objectives: The purpose of this study is to evaluate whether coronary flow capacity (CFC) improves discrimination of patients at risk for major adverse cardiac events (MACE) compared with coronary flow reserve (CFR) alone, and to study the diagnostic and prognostic implications of CFC in relation to contemporary diagnostic tests for ischemic heart disease (IHD), including fractional flow reserve (FFR).

01 noviembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Combining Baseline Distal-to-Aortic Pressure Ratio and Fractional Flow Reserve in the Assessment of Coronary Stenosis Severity

Mauro Echavarría-Pinto, MD∗,†,‡; Tim P. van de Hoef, MD∗,†,‡; Martijn A. van Lavieren, MSc‡; Sukhjinder Nijjer, MBChB§; Borja Ibañez, MD, PhD∗,†; Stuart Pocock, PhD†; Alicia Quirós, PhD∗; Justin Davies, MBBS, PhD§; Martijn Meuwissen, MD, PhD‖; Patrick W. Serruys, MD, PhD§; Carlos Macaya, MD, PhD∗,¶; Jan J. Piek, MD, PhD‡; Javier Escaned, MD, PhD∗,†,¶

Objectives: This study sought to understand the physiological basis of baseline distal-to-aortic pressure ratio (Pd/Pa) and fractional flow reserve (FFR) agreement and discordance, using coronary flow reserve (CFR), stenosis resistance, and microcirculatory resistance measurements, and form there, to investigate the potential value of combining Pd/Pa with FFR in the diagnostic rationale.

01 noviembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty. Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter)

Harald Rittger, MD∗; Matthias Waliszewski, PhD†; Johannes Brachmann, MD‡; Wolfgang Hohenforst-Schmidt, MD∗; Marc Ohlow, MD§; Andreas Brugger, MD‖; Holger Thiele, MD¶; Ralf Birkemeyer, MD#; Volkhard Kurowski, MD∗∗; Christian Schlundt, MD††; Stefan Zimmermann, MD‡‡; Sandra Lonke, MD∗; Moritz von Cranach, MD§§; Sinisa Markovic, MD‖‖; Werner G. Daniel, MD††; Stephan Achenbach, MD††; Jochen Wöhrle, MD‖‖

Objectives: The intention this PEPCAD-DES (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter) study update was to demonstrate the safety and efficacy of paclitaxel-coated balloon (PCB) angioplasty in patients with DES-ISR at 3 years.